Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Solid Tumors 2Neoplasms 2Melanoma 2Recurrence 1Pancreatic Adenocarcinoma 1Advanced/Metastatic Solid Tumors 1Adenocarcinoma Pancreas 1

Interventions

Gemcitabine 7130-nm albumin-bound paclitaxel 5Fluorouracil 3Albumin-Bound Paclitaxel 3dehydroftorafur 2Taxes 2Oxaliplatin 2tocilizumab 1selicrelumab 1niraparib 1cobimetinib 1atezolizumab 1Tiragolumab 1Resistance Training 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiotherapy, Conformal 1Pancreatectomy 1PEGPH20 1Nivolumab 1Leucovorin 1Irinotecan 1Ipilimumab 1Interleukin 1 Receptor Antagonist Protein 1Erlotinib Hydrochloride 1Electronic Health Records 1Cisplatin 1Bevacizumab 14-fluorobenzoyl-TN-14003 13-aminopyridine-2-carboxaldehyde thiosemicarbazone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pancreatic Adenocarcinoma × selicrelumab × Clear all
NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
341 enrolled 28 charts
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡